Immunome Inc.

Immunome Inc. (IMNM) priced its initial public offering on Oct 5, 2020 at $12.00 per share, within its $11.00–$13.00 range, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $120.4M. Ladenburg Thalmann was lead-left underwriter, joined by Chardan. Cooley advised the company and Goodwin Procter advised the underwriters.

Immunome Inc. is a biopharmaceutical company using its human memory B cell platform to discover antibody therapeutics and their targets for cancer and infectious diseases. It has processed more than 150 cancer patient memory B cell samples and screened over 250,000 hybridomas.

Status

IPO

Ticker

IMNM

Exchange

Nasdaq Capital Market

Priced

Oct 5, 2020

IPO price

$12.00

Price range

$11.00–$13.00

Market cap at IPO price

$120.4M

First filed

Sep 9, 2020

Underwriters

Ladenburg Thalmann and Chardan

Company counsel

Cooley

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

WA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.